Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.7
3.2
Journals
Life
Special Issues
Migraine Neuroscience: From Bench to Bedside
share announcement

Migraine Neuroscience: From Bench to Bedside

A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Medical Research".

Deadline for manuscript submissions: closed (18 October 2023) | Viewed by 3969

Special Issue Editors

Dr. Adina Maria Roceanu

E-Mail Website
Guest Editor
Neurology Department, University Emergency Hospital Bucharest, Bucharest, Romania
Interests: neurology; adults with newly diagnosed focal epilepsy; parkinson disease; migraine; multiple sclerosis
Prof. Dr. Rigmor Højland Jensen

E-Mail Website
Guest Editor
Danish Headache Center, Department of Neurology, Rigshospitalet-Glostrup, University of Copenhagen, 2600 Glostrup, Denmark
Interests: epidemiology of headache; multidisciplinary treatment of headache; medication overuse headache; cluster headache; idiopathic intracranial hypertension and CSF-regulation; pathophysiology of tension-type headache and neurological pain

Special Issue Information

Dear Colleagues,

The most frequent neurological disorder is headache, and promising new treatment strategies are emerging, especially for migraine. The third (alfa) International Classification of Headache Disorders, published in 2018 by the International Headache Society, describes more than 200 types of headaches. Migraine is a highly disabling primary headache that affects more than 1 billion people worldwide.

Migraine is characterized by recurrent episodes of severe unilateral throbbing headache, lasting 4-72 hours, associated with nausea/vomiting and with sensitivity to light, sound and head movement (migraine without aura). About one third of migraineurs experience fully reversible neurological symptoms (visual, sensitive) that precede or accompany the headache (migraine with aura).

The neuropeptide Calcitonin Gene-Related Peptide (CGRP) plays a key role in migraine pathophysiology. New therapeutically active agents specifically targeting CGRP or its receptor were developed for migraine treatment: 

  • For acute migraine treatment—small oral molecules: gepants - ubrogepant, rimegepant.
  • For migraine prevention—large parenteral molecules: monoclonal antibodies (mAbs) targeting the peptide CGRP (fremanezumab, galcanezumab and eptinezumab) or its receptor (erenumab).

Other molecules are also involved in migraine pathophysiology such as the pituitary adenylate cyclase-activating peptide (PACAP), and neutralizing monoclonal antibodies to PACAP are under development. In this Special Issue, we will describe the most recent progress in diagnosis, red and green flags and treatment strategies.

Dr. Adina Maria Roceanu
Prof. Dr. Rigmor Højland Jensen
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • migraine with aura
  • migraine without aura
  • CGRP
  • gepants
  • anti-CGRP mAbs

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

12 pages, 635 KiB  
Review
Headache and Other Pain Syndromes in Multiple Sclerosis: A Narrative Review
by Carmen Adella Sîrbu, Andreea Ruxandra Rotaru, Florina Anca Antochi, Andreea Plesa, Aida Mihaela Manole and Adina Maria Roceanu
Life 2024, 14(1), 87; https://0-doi-org.brum.beds.ac.uk/10.3390/life14010087 - 5 Jan 2024
Viewed by 1883
Abstract
Multiple sclerosis is a chronic and progressive neurological disease, with an important socio-economic burden. Over time, an increased incidence of headaches like migraines and tension headaches has been observed among these patients. Headaches have not been considered as multiple sclerosis-related symptoms, even representing [...] Read more.
Multiple sclerosis is a chronic and progressive neurological disease, with an important socio-economic burden. Over time, an increased incidence of headaches like migraines and tension headaches has been observed among these patients. Headaches have not been considered as multiple sclerosis-related symptoms, even representing a red flag for multiple sclerosis diagnosis. It is uncertain whether the headache–multiple sclerosis association could be explained by the presence of common triggers or a common physiopathological mechanism (involvement of tertiary B-cell follicles). An important differential diagnosis is between multiple sclerosis attacks and migraines with aura, which can also be associated with neurological deficits. Another important aspect is the occurrence or exacerbation of the cephalalgic syndrome after the initiation of therapy for multiple sclerosis (DMTs), or the improvement of headache after the initiation of certain DMT drugs. In addition to headaches, individuals diagnosed with multiple sclerosis often report experiencing diverse pain syndromes, contributing to an additional decline in their overall quality of life. These syndromes are frequently neglected, the focus being on slowing down the progression of neurological deficits. This review aims to evaluate the characteristics of multiple-sclerosis-related headaches (frequency, possible correlation with attacks, and disease-modifying therapies) and the key distinctions in imaging characteristics between demyelinating lesions in multiple sclerosis and those observed in cases of primary headaches. Full article
(This article belongs to the Special Issue Migraine Neuroscience: From Bench to Bedside)
►▼ Show Figures

Figure 1

14 pages, 849 KiB  
Review
Migraine Comorbidities
by Dan Iulian Cuciureanu, Cătălina Elena Bistriceanu, Georgiana-Anca Vulpoi, Tudor Cuciureanu, Florina Antochi and Adina-Maria Roceanu
Life 2024, 14(1), 74; https://0-doi-org.brum.beds.ac.uk/10.3390/life14010074 - 2 Jan 2024
Cited by 1 | Viewed by 1746
Abstract
Novel knowledge about the interrelationships and reciprocal effects of migraine and epilepsy, migraine and mood disorders, or migraine and irritable bowel syndrome has emerged in recent decades. Over time, comorbid pathologies associated with migraine that share common physiopathological mechanisms were studied. Among these [...] Read more.
Novel knowledge about the interrelationships and reciprocal effects of migraine and epilepsy, migraine and mood disorders, or migraine and irritable bowel syndrome has emerged in recent decades. Over time, comorbid pathologies associated with migraine that share common physiopathological mechanisms were studied. Among these studied pathologies is epilepsy, a disorder with common ion channel dysfunctions as well as dysfunctions in glutamatergic transmission. A high degree of neuronal excitement and ion channel abnormalities are associated with epilepsy and migraine and antiepileptic drugs are useful in treating both disorders. The coexistence of epilepsy and migraine may occur independently in the same individual or the two may be causally connected. The relationship between cortical spreading depression (CSD) and epileptic foci has been suggested by basic and clinical neuroscience research. The most relevant psychiatric comorbidities associated with migraine are anxiety and mood disorders, which influence its clinical course, treatment response, and clinical outcome. The association between migraine and major depressive disorder can be explained by a robust molecular genetic background. In addition to its role as a potent vasodilator, CGRP is also involved in the transmission of nociception, a phenomenon inevitably linked with the stress and anxiety caused by frequent migraine attacks. Another aspect is the role of gut microbiome in migraine’s pathology and the gut–brain axis involvement. Irritable bowel syndrome patients are more likely to suffer migraines, according to other studies. There is no precise explanation for how the gut microbiota contributes to neurological disorders in general and migraines in particular. This study aims to show that migraines and comorbid conditions, such as epilepsy, microbiota, or mood disorders, can be connected from the bench to the bedside. It is likely that these comorbid migraine conditions with common pathophysiological mechanisms will have a significant impact on best treatment choices and may provide clues for future treatment options. Full article
(This article belongs to the Special Issue Migraine Neuroscience: From Bench to Bedside)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop